Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Allison Pohle, reporter at The Wall Street Journal, breaks down airline chaos, surprise winners, and what the latest rankings mean for your next flight.
Jason Chinnock discusses Ducati’s 100th anniversary, blending a century of racing heritage with innovation, off-road expansion, and plans for the next 100 years
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
For Trump, markets matter more than polls. Luke Broadwater, White House correspondent for The New York Times, examines how Wall Street guides decisions.
As political and economic uncertainty rises, Americans are seeking second passports and golden visas. Latitude Group’s CEO explains what’s driving the surge.
As AI and electrification drive record power demand, nuclear energy returns to the spotlight. Lightbridge CEO explains how advanced fuel could reshape the grid.
